Pfizer has said their child-size dose of the Covid-19 vaccine is 91% effective at preventing symptomatic infection in 5-11-year-olds.
The study was made public as the US is considering extending vaccines to this age cohort.
The Food and Drug Administration (FDA) is due to publish their own independent analysis of the study before giving a recommendation.
If the FDA authorises the vaccine for children in this age cohort, the Centres for Disease Control and Prevention (CDC) will make the final decision about who should receive them.
The Biden Administration has purchased enough child-size vaccines to inoculate the nation’s 28 million children in this age cohort.
The Pfizer study focused on 2,268 children aged between 5-11, who received two doses three weeks apart, either the vaccine or a placebo.
Each dose was one third the amount given to adults.
IMAGE – Army Spc. Angel Laureano holds a vial of the COVID-19 vaccine, Walter Reed National Military Medical Center, Bethesda, Md., Dec. 14, 2020. (DoD photo by Lisa Ferdinando)